Viewpoints

Opinion and analysis on managing care from experts and KOLs

Contributing Voices
Karen Kobelski
It’s a costly time for hospitals. In the report, “Trends in Hospital Inpatient Drug Costs: Issues and Challenges,” the National Opinion Research Center found that inpatient drug costs per admission are skyrocketing, having increased 38.7 percent in the three-year period from 2014 to 2016. These…
Viewpoint
Thomas Martin
The need for real-time data in health care is universal, but it is particularly pressing for post-acute providers, who are now joining their hospital and health system peers in being held responsible for patient outcomes. CMS is watching.
Contributing Voices
John S. Linehan

Arizona, Virginia, and West Virginia are leading the pack. Bills have been introduced in several states that would effectively ban copay accumulators.

Viewpoint
Jake Frenz

The managed care industry faces regulatory pressure to halt the rising cost of prescription drugs, but real change can be found by disrupting traditional PBMs

Viewpoint
Erik Johnson
There is near-universal consensus that “value-based care” is a good and worthy objective. In any instance when unanimity embraces an idea, a thoughtful person might ask whether there’s true agreement or perhaps just a cone of vagueness that accommodates a variety of opinions and lets eyes of the…
Viewpoint
Erik Johnson
As plans and providers collaborate to manage post-discharge care, they will also need to take heed of the nonclinical variables. Limitations in performing activities of daily living (ADLs) and social determinants of health have as great an impact on health care spending among the elderly as the presence of chronic conditions.
Viewpoint
Sanjiv Luthra
Danny Sands, MD
Monitoring medication management with retroactive measures provides only partial insights. Real-time help that combines digital tools with provider support is needed.
Viewpoint
John S. Linehan, JD
Drug manufacturers have relied on coupons to promote access to branded drugs by reducing patients’ out-of-pocket costs. Insurers and PBMs, on the other hand, have opposed coupons because they undermine the effectiveness of cost-sharing requirements and benefit designs that incentivize cost-effective drug prescribing and purchasing choices.